Bachem Holding AG stock analysis
Bachem Holding AG (BCHMF) Stock Price & Analysis
BCHMF Stock Chart & Stats
- Day’s Range
- $92.71 - $96.90
- 52-Week Range
- $58.30 - $108.92
- Previous Close
- $96.38
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- $7.11B
- Enterprise Value
- $5.83B
- Total Cash (Recent Filing)
- $51.57M
- Total Debt (Recent Filing)
- $208.10M
- Price to Earnings (P/E)
- 40.0
- Beta
- 1.18
- Next Earnings
- Mar 04, 2027 (Est.)
- EPS Estimate
- 1.89
- Last Dividend Ex-Date
- May 05, 2026
- Dividend Yield
- 0.61%
Bulls Say, Bears Say
Bulls Say
Very Low Leverage
The exceptionally conservative capital structure reduces financial strain and preserves flexibility for capacity investment, customer programs, or downturns. A large and growing equity base also supports resilience because profitability is not dependent on heavy borrowing or leverage.
Resilient Profitability And Revenue Growth
Steady multi-year revenue expansion and solid profitability indicate durable demand for Bachem’s peptide and oligonucleotide manufacturing capabilities. This earnings base can support continued investment and customer support while providing operating resilience across development and commercial projects.
Specialized Peptide And Oligonucleotide CDMO Position
Bachem’s specialized CDMO model serves customers across drug discovery, clinical development, and commercial-scale production. Supporting complex, regulated therapeutics can deepen customer relationships and create opportunities for recurring manufacturing demand as successful programs advance.
Bears Say
Persistent Negative Free Cash Flow
Repeated negative free cash flow means substantial investment spending or working-capital needs are absorbing internally generated cash. If this pattern persists, Bachem may have less flexibility to fund expansion, dividends, or other strategic priorities without relying on external financing.
Gradual Margin Compression
Although current margins remain healthy, the downward trend suggests that cost growth, business mix, or investment requirements are taking a larger share of revenue. Continued compression could reduce the earnings benefit of future sales growth and weaken operating leverage over time.
Recent Debt Increase
The 2025 increase in total debt is notable against Bachem’s previously near-zero leverage profile. While leverage remains very low, a continued buildup would gradually reduce balance-sheet conservatism and could add financing costs or constrain future capital allocation.
Bachem Holding AG News
BCHMF FAQ
What was Bachem Holding AG’s price range in the past 12 months?
What is Bachem Holding AG’s market cap?
When is Bachem Holding AG’s upcoming earnings report date?
How were Bachem Holding AG’s earnings last quarter?
Is Bachem Holding AG overvalued?
Does Bachem Holding AG pay dividends?
What is Bachem Holding AG’s EPS estimate?
What happened to Bachem Holding AG’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Bachem Holding AG?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Bachem Holding AG
Bachem Holding AG serves pharmaceutical and biotechnology companies globally, providing products crucial for research, clinical development, and commercial use. The company's primary focus is on the design, manufacturing, and regulatory support for peptide active pharmaceutical ingredients (APIs), specifically targeting novel peptide and oligonucleotide chemical entities (NCEs). Additionally, Bachem offers commercially available NCEs and generic compounds. Its comprehensive service portfolio includes project management, quality assurance and regulatory guidance, analytical testing, production adhering to Good Manufacturing Practices (GMP), manufacturing for research purposes, and expertise in supply chain and vertical integration. Established in 1971, Bachem Holding AG is headquartered in Bubendorf, Switzerland, and functions as a subsidiary of Ingro Finanz AG.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Anne-Kathrin Stoller
- Employees
- 2,725
- Website
- www.bachem.com
- Address
- Hauptstrasse 144, Bubendorf, BL, 4416, CH
Bachem Holding AG (BCHMF) Earnings & Revenues
BCHMF Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 3 | 12 |
| Technical Analysis | 5 | 3 | 2 |
| Moving Averages | 2 | 0 | 10 |
Similar Stocks
| Company | Price & Change | Follow |
|---|---|---|
| CH:LONNLonza Group Ltd |










